{"Title": ["Validea Peter Lynch Strategy Daily Upgrade Report - 5/15/2020", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 4/19/2020", "Validea Peter Lynch Strategy Daily Upgrade Report - 4/15/2020", "Validea Motley Fool Strategy Daily Upgrade Report - 3/31/2020", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 3/15/2020", "Validea Peter Lynch Strategy Daily Upgrade Report - 2/29/2020", "Validea's Top Five Healthcare Stocks Based On John Neff - 1/19/2020", "Validea's Top Five Healthcare Stocks Based On John Neff - 12/15/2019", "Validea Peter Lynch Strategy Daily Upgrade Report - 5/15/2020", "Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%", "Zacks.com featured expert Kevin Matras highlights: Darden Restaurants, Best Buy, BioSpecifics Technologies and ONEOK", "4 Top Stocks to Buy for Superb Earnings Growth", "BioSpecifics (BSTC) Upgraded to Strong Buy: Here's What You Should Know", "What's in Store for BioSpecifics (BSTC) This Earnings Season?", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 2/17/2019", "Validea's Top Five Healthcare Stocks Based On Motley Fool - 2/17/2019", "Bullish Two Hundred Day Moving Average Cross - BSTC", "Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?", "Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza", "INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data", "Weakness Seen in Champions Oncology (CSBR) Estimates: Should You Stay Away?", "Karyopharm Files MAA for Myeloma Candidate Selinexor in EU", "Neurocrine Gives Ingrezza Sales View, Updates on Pipeline", "Verrica (VRCA) Catches Eye: Stock Jumps 6.9%", "BioSpecifics (BSTC) Upgraded to Buy: Here's What You Should Know", "Flexion Starts Phase III Enrollment on Zilretta for Hip OA", "Portola Up as Large-Scale Andexxa Production Gets FDA Nod", "Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis", "Is BioSpecifics Technologies (BSTC) Outperforming Other Medical Stocks This Year?", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 12/16/2018", "Validea's Top Five Healthcare Stocks Based On Motley Fool - 12/16/2018", "Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya", "Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study", "Why Tilray (TLRY) Could Be Positioned for a Slump", "Jazz (JAZZ) Increases Share Buyback Authorization by $400M", "Validea Motley Fool Strategy Daily Upgrade Report - 12/11/2018", "Theravance Pipeline Strong, Plans Yupelri Launch by Year End", "Theravance's Respiratory Disease JAK Inhibitor Enters Phase I", "Theravance JAK Inhibitor Enters Phase II for Crohn's Disease", "IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance", "Novan Announces Top-Line Data From Mid-Stage Molluscum Study", "TESARO (TSRO) Jumps: Stock Rises 5.4%", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 11/18/2018", "Validea Martin Zweig Strategy Daily Upgrade Report - 11/13/2018", "BioSpecifics Technologies (BSTC) Q3 Earnings and Revenues Beat Estimates", "What's in the Cards for BioSpecifics (BSTC) in Q3 Earnings?", "BioSpecifics Technologies (BSTC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release", "Affimed Down After Clinical Hold on Two Early-Stage Studies", "Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher", "BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher", "Champions Oncology (CSBR) Soars: Stock Adds 10.7% in Session", "4 Stocks With Recent Price Strength to Maximize Your Gains", "Infinity Pharmaceuticals (INFI) Looks Good: Stock Adds 6.5% in Session", "Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?", "Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error", "Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session", "Zacks.com highlights: OptimizeRX, Verso, BioSpecifics Technologies and Luxfer Holdings", "Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap", "Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher", "Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status", "Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda", "Molecular Templates Surges 50%, Inks Cancer Deal With Takeda", "Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies", "5 Stocks With Recent Price Strength to Strengthen Portfolio", "Why Lannett (LCI) Could Be Positioned for a Slump", "Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 6.2% Higher", "Ironwood Stock Up, Heart Candidate Gets Fast Track Status", "KemPharm Posts Positive Top-Line Results on KP415 Prodrug", "Tilray (TLRY) Looks Good: Stock Adds 8.5% in Session", "The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor", "5 Top-Ranked Nasdaq Stocks Defying the Worst September Start", "Tesaro (TSRO) Surges: Stock Moves 5.5% Higher", "United Therapeutics In-Licenses Rights to IPF Candidate", "Biogen Begins Phase III Study on Ischemic Stroke Candidate", "4 Stocks With Recent Price Strength to Maximize Your Gains", "Affimed (AFMD) Soars: Stock Adds 10.8% in Session", "Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol", "Portola Pharmaceuticals (PTLA) Jumps: Stock Rises 9.1%", "Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe", "Ironwood's Linzess Gets Approval in Japan for New Indication", "Zacks.com highlights: Verso, Johnson Outdoors, BioSpecifics Technologies and Luxfer Holdings", "Biogen Begins Phase III Study on Ischemic Stroke Candidate", "4 Stocks With Recent Price Strength to Maximize Your Gains", "5 Stocks With Recent Price Strength to Enhance Your Returns", "BioSpecifics Technologies (BSTC) Q2 Earnings Top Estimates", "Can The Uptrend Continue for BioSpecifics Technologies (BSTC)?", "Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9%", "What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)", "VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market", "Falling Earnings Estimates Signal Weakness Ahead for Karyopharm Therapeutics (KPTI)", "Why Flexion Therapeutics (FLXN) Could Be Positioned for a Slump", "Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session", "Madrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session", "Nektar (NKTR) Surges: Stock Moves 11% Higher", "ImmunoGen (IMGN) Soars: Stock Adds 10.3% in Session", "RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher", "Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in Session", "New Strong Sell Stocks for December 1st", "New Strong Sell Stocks for November 27th", "New Strong Sell Stocks for November 22nd", "New Strong Sell Stocks for November 17th", "New Strong Sell Stocks for September 5th", "New Strong Sell Stocks for September 1st", "Validea Motley Fool Strategy Daily Upgrade Report - 8/25/2017", "New Strong Sell Stocks for December 6th", "New Strong Sell Stocks for August 15th", "Validea Motley Fool Strategy Daily Upgrade Report - 8/10/2017", "Will BioSpecifics Technologies (BSTC) Continue to Surge Higher?", "PAREXEL International (PRXL) Set to Acquire ExecuPharm", "Mid-Morning Market Update: Markets Open Higher; Lennar Tops Q3 Expectations", "Can The Uptrend Continue for BioSpecifics Technologies (BSTC)?", "Foamix Pharmaceuticals (FOMX) Jumps: Stock Rises 15.7%", "New Strong Sell Stocks for August 21st", "Sage Therapeutics: Breakthrough Status for Depression Drug", "AstraZeneca Asthma Drug Symbicort Positive in Safety Trial", "Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%", "What Makes Collegium Pharmaceutical (COLL) a Strong Sell?", "The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences", "Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?", "Forget Mylan, Buy These 3 Drug Stocks Instead", "Karyopharm Reports Positive Multiple Myeloma Study Data", "Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Up 6.3%", "New Strong Sell Stocks for May 13th", "Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus", "Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook", "BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss", "ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)", "Why BioSpecifics Technologies (BSTC) Stock Might be a Great Pick", "New Strong Buy Stocks for August 22nd", "Mid-Day Market Update: Joy Global Drops On Earnings Miss; Methode Electronics Shares Spike Higher", "Mid-Day Market Update: National Penn Bancshares Surges On Acquisition News; Vera Bradley Shares Slide", "BioSpecifics Announces Label Expansion for Xiaflex in EU - Analyst Blog", "Auxilium Pharma Cuts Guidance - Analyst Blog", "Auxilium Pharma Beats on Q4 Earnings - Analyst Blog", "Zacks Rank #1 Additions for Monday - Tale of the Tape", "Pre-Market Earnings Report for March 14, 2016 : IPAR, PGEM, INO, TA, RDNT, KPTI, BSTC, NERV, EARS, STRL, VCEL, UCP", "Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% - Tale of the Tape", "Positive Data on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog", "Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles - Analyst Blog", "Update on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog", "Pipeline Progress at Auxilium Pharma - Analyst Blog", "Auxilium Up on Peyronie's Approval - Analyst Blog", "BioSpecifics Technologies Corp. (BSTC) in Focus: Stock Moves 6.5% Higher - Tale of the Tape", "Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape", "Cadence Pharmaceuticals Inc. (CADX) Jumps: Stock Rises 6.2% - Tale of the Tape", "Zacks #1 Rank Additions for Tuesday - Tale of the Tape", "Data on Auxilium Pharma's Xiaflex - Analyst Blog", "Regulatory Setback for Forest/Gedeon - Analyst Blog", "QLT (QLTI) Surges: Stock Moves 11.8% Higher - Tale of the Tape", "BioSpecifics Technologies (BSTC) Looks Good: Stock Moves 9.5% Higher - Tale of the Tape", "Will BioSpecifics Technologies Corp. (BSTC) Continue to Surge Higher? - Tale of the Tape", "Zacks #1 Rank Additions for Monday - Tale of the Tape", "Strength Seen in Cadence Pharmaceuticals (CADX): Stock Soars 34% - Tale of the Tape", "Data on Auxilium Pharma's Xiaflex - Analyst Blog", "Strength Seen in Pharmacyclics (PCYC): Stock Rises 10.1% - Analyst Blog", "AUXL's Xiaflex Decision Delayed - Analyst Blog", "J&J Acquires Aragon - Analyst Blog", "Can the Recent Uptrend Continue for BioSpecifics Technologies Corp. (BSTC)? - Tale of the Tape", "Company News for May 13, 2013 - Corporate Summary", "Zacks #1 Rank Additions for Monday - Tale of the Tape", "Strength Seen in Cadence Pharmaceuticals (CADX): Stock Soars 34% - Tale of the Tape", "Weak Quarter from Auxilium Pharma - Analyst Blog", "A Profitable Quarter for Auxilium - Analyst Blog", "Loss Narrows at Auxilium - Analyst Blog", "Merck Reports Strong Q3 Results on Gardasil and Diabetes Med", "Biotech Bargains: Biotech Analysts See Buying Opportunities From Selloff", "Positive Data on BSTC's Xiaflex - Analyst Blog"], "Elapsed Time": ["MAY 15, 2020", "APR 19, 2020", "APR 15, 2020", "MAR 31, 2020", "MAR 15, 2020", "FEB 29, 2020", "JAN 19, 2020", "DEC 15, 2019", "MAY 15, 2020", "APR 16, 2019", "MAR 25, 2019", "MAR 22, 2019", "MAR 20, 2019", "MAR 5, 2019", "FEB 17, 2019", "FEB 17, 2019", "JUL 22, 2019", "JAN 17, 2019", "JAN 11, 2019", "JAN 10, 2019", "JAN 10, 2019", "JAN 9, 2019", "JAN 7, 2019", "JAN 4, 2019", "JAN 28, 2019", "JAN 3, 2019", "JAN 2, 2019", "DEC 28, 2018", "DEC 25, 2018", "DEC 16, 2018", "DEC 16, 2018", "DEC 12, 2018", "JAN 3, 2019", "DEC 11, 2018", "DEC 11, 2018", "DEC 11, 2018", "NOV 29, 2018", "NOV 28, 2018", "NOV 21, 2018", "NOV 21, 2018", "DEC 11, 2018", "NOV 20, 2018", "NOV 18, 2018", "NOV 13, 2018", "NOV 9, 2018", "NOV 6, 2018", "NOV 2, 2018", "OCT 9, 2018", "NOV 20, 2018", "OCT 5, 2018", "OCT 5, 2018", "OCT 5, 2018", "OCT 3, 2018", "OCT 2, 2018", "OCT 1, 2018", "SEP 28, 2018", "OCT 8, 2018", "SEP 27, 2018", "SEP 27, 2018", "SEP 26, 2018", "SEP 21, 2018", "SEP 20, 2018", "SEP 20, 2018", "SEP 19, 2018", "SEP 28, 2018", "SEP 18, 2018", "SEP 14, 2018", "SEP 12, 2018", "SEP 11, 2018", "SEP 11, 2018", "SEP 10, 2018", "SEP 6, 2018", "SEP 18, 2018", "SEP 5, 2018", "SEP 4, 2018", "AUG 30, 2018", "AUG 28, 2018", "AUG 27, 2018", "AUG 27, 2018", "AUG 22, 2018", "SEP 5, 2018", "SEP 5, 2018", "SEP 4, 2018", "AUG 17, 2018", "AUG 9, 2018", "JUL 6, 2018", "MAY 9, 2018", "APR 10, 2018", "AUG 22, 2018", "APR 6, 2018", "APR 6, 2018", "MAR 28, 2018", "MAR 20, 2018", "FEB 15, 2018", "FEB 1, 2018", "JAN 30, 2018", "APR 9, 2018", "DEC 1, 2017", "NOV 27, 2017", "NOV 22, 2017", "NOV 17, 2017", "SEP 5, 2017", "SEP 1, 2017", "AUG 25, 2017", "DEC 6, 2017", "AUG 15, 2017", "AUG 10, 2017", "NOV 18, 2016", "SEP 27, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 13, 2016", "AUG 21, 2017", "SEP 7, 2016", "SEP 1, 2016", "SEP 1, 2016", "AUG 30, 2016", "AUG 29, 2016", "AUG 29, 2016", "AUG 26, 2016", "SEP 7, 2016", "AUG 18, 2016", "MAY 13, 2016", "MAY 11, 2016", "MAY 11, 2016", "MAY 11, 2016", "MAY 11, 2016", "APR 12, 2016", "AUG 22, 2016", "SEP 3, 2015", "AUG 18, 2015", "FEB 5, 2015", "APR 30, 2014", "MAR 3, 2014", "MAR 3, 2014", "MAR 11, 2016", "FEB 19, 2014", "JAN 9, 2014", "JAN 2, 2014", "DEC 27, 2013", "DEC 16, 2013", "DEC 9, 2013", "DEC 9, 2013", "FEB 26, 2014", "DEC 4, 2013", "DEC 3, 2013", "NOV 22, 2013", "NOV 22, 2013", "NOV 21, 2013", "NOV 19, 2013", "NOV 19, 2013", "DEC 9, 2013", "NOV 18, 2013", "OCT 11, 2013", "SEP 27, 2013", "AUG 29, 2013", "AUG 20, 2013", "AUG 12, 2013", "MAY 13, 2013", "NOV 18, 2013", "NOV 18, 2013", "NOV 8, 2012", "AUG 2, 2012", "MAY 14, 2012", "NOV 6, 2011", "AUG 16, 2011", "APR 1, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-5-15-2020-2020-05-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-4-19-2020-2020-04-19", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-4-15-2020-2020-04-15", "https://www.nasdaq.com/articles/validea-motley-fool-strategy-daily-upgrade-report-3-31-2020-2020-03-31", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-2-29-2020-2020-02-29", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-5-15-2020-2020-05-15", "https://www.nasdaq.com/articles/achaogen-akao-files-for-bankruptcy-shares-plunge-65-2019-04-16-0", "https://www.nasdaq.com/articles/zacks.com-featured-expert-kevin-matras-highlights%3A-darden-restaurants-best-buy", "https://www.nasdaq.com/articles/4-top-stocks-buy-superb-earnings-growth-2019-03-22", "https://www.nasdaq.com/articles/biospecifics-bstc-upgraded-to-strong-buy%3A-heres-what-you-should-know-2019-03-20", "https://www.nasdaq.com/articles/whats-in-store-for-biospecifics-bstc-this-earnings-season-2019-03-05", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-martin-zweig-2172019-2019-02-17", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-motley-fool-2172019-2019-02-17", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-bstc-2019-07-22", "https://www.nasdaq.com/articles/is-biospecifics-technologies-bstc-stock-outpacing-its-medical-peers-this-year-2019-01-17", "https://www.nasdaq.com/articles/ocular-ocul-submits-an-snda-for-eye-pain-drug-dextenza-2019-01-11", "https://www.nasdaq.com/articles/insys-therapeutics-rises-on-dose-ranging-allergy-study-data-2019-01-10", "https://www.nasdaq.com/articles/weakness-seen-in-champions-oncology-csbr-estimates%3A-should-you-stay-away-2019-01-10", "https://www.nasdaq.com/articles/karyopharm-files-maa-for-myeloma-candidate-selinexor-in-eu-2019-01-09", "https://www.nasdaq.com/articles/neurocrine-gives-ingrezza-sales-view-updates-on-pipeline-2019-01-07", "https://www.nasdaq.com/articles/verrica-vrca-catches-eye%3A-stock-jumps-6.9-2019-01-04", "https://www.nasdaq.com/articles/biospecifics-bstc-upgraded-to-buy%3A-heres-what-you-should-know-2019-01-28", "https://www.nasdaq.com/articles/flexion-starts-phase-iii-enrollment-on-zilretta-for-hip-oa-2019-01-03", "https://www.nasdaq.com/articles/portola-up-as-large-scale-andexxa-production-gets-fda-nod-2019-01-02", "https://www.nasdaq.com/articles/spectrum-pharma-files-bla-for-neutropenia-candidate-rolontis-2018-12-28", "https://www.nasdaq.com/articles/is-biospecifics-technologies-bstc-outperforming-other-medical-stocks-this-year-2018-12-25", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-martin-zweig-12162018-2018-12-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-motley-fool-12162018-2018-12-16", "https://www.nasdaq.com/articles/portola-ptla-down-as-chmp-defers-review-date-for-ondexxya-2018-12-12", "https://www.nasdaq.com/articles/spectrum-pharma-fully-enrolls-1st-cohort-in-poziotinib-study-2019-01-03", "https://www.nasdaq.com/articles/why-tilray-tlry-could-be-positioned-for-a-slump-2018-12-11", "https://www.nasdaq.com/articles/jazz-jazz-increases-share-buyback-authorization-by-%24400m-2018-12-11", "https://www.nasdaq.com/articles/validea-motley-fool-strategy-daily-upgrade-report-12112018-2018-12-11", "https://www.nasdaq.com/articles/theravance-pipeline-strong-plans-yupelri-launch-by-year-end-2018-11-29", "https://www.nasdaq.com/articles/theravances-respiratory-disease-jak-inhibitor-enters-phase-i-2018-11-28", "https://www.nasdaq.com/articles/theravance-jak-inhibitor-enters-phase-ii-for-crohns-disease-2018-11-21", "https://www.nasdaq.com/articles/intelgenxs-nda-resubmission-for-rizaport-gets-fda-acceptance-2018-11-21", "https://www.nasdaq.com/articles/novan-announces-top-line-data-from-mid-stage-molluscum-study-2018-12-11", "https://www.nasdaq.com/articles/tesaro-tsro-jumps%3A-stock-rises-5.4-2018-11-20", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-martin-zweig-11182018-2018-11-18", "https://www.nasdaq.com/articles/validea-martin-zweig-strategy-daily-upgrade-report-11132018-2018-11-13", "https://www.nasdaq.com/articles/biospecifics-technologies-bstc-q3-earnings-and-revenues-beat-estimates-2018-11-09", "https://www.nasdaq.com/articles/whats-in-the-cards-for-biospecifics-bstc-in-q3-earnings-2018-11-06", "https://www.nasdaq.com/articles/biospecifics-technologies-bstc-earnings-expected-to-grow%3A-what-to-know-ahead-of-next-weeks", "https://www.nasdaq.com/articles/affimed-down-after-clinical-hold-on-two-early-stage-studies-2018-10-09", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-glmd-in-focus%3A-stock-moves-6.2-higher-2018-11-20", "https://www.nasdaq.com/articles/biolinerx-blrx-in-focus%3A-stock-moves-7.5-higher-2018-10-05", "https://www.nasdaq.com/articles/champions-oncology-csbr-soars%3A-stock-adds-10.7-in-session-2018-10-05", "https://www.nasdaq.com/articles/4-stocks-with-recent-price-strength-to-maximize-your-gains-2018-10-05", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-infi-looks-good%3A-stock-adds-6.5-in-session-2018-10-03", "https://www.nasdaq.com/articles/is-biospecifics-technologies-bstc-stock-outpacing-its-medical-peers-this-year-2018-10-02", "https://www.nasdaq.com/articles/endo-recalls-2-lots-of-robaxin-tablets-due-to-labeling-error-2018-10-01", "https://www.nasdaq.com/articles/aldeyra-therapeutics-aldx-looks-good%3A-stock-adds-7.5-in-session-2018-09-28", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-optimizerx-verso-biospecifics-technologies-and-luxfer-holdings-2018", "https://www.nasdaq.com/articles/aldeyra-surges-on-positive-dry-eye-study-data-on-reproxalap-2018-09-27", "https://www.nasdaq.com/articles/adamis-pharmaceuticals-admp-in-focus%3A-stock-moves-8-higher-2018-09-27", "https://www.nasdaq.com/articles/portolas-ptla-lymphoma-candidate-gets-orphan-drug-status-2018-09-26", "https://www.nasdaq.com/articles/galectins-gr-md-02-positive-in-phase-ib-study-with-keytruda-2018-09-21", "https://www.nasdaq.com/articles/molecular-templates-surges-50-inks-cancer-deal-with-takeda-2018-09-20", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-champions-oncology-staar-surgical-boingo-wireless-verso-and", "https://www.nasdaq.com/articles/5-stocks-with-recent-price-strength-to-strengthen-portfolio-2018-09-19", "https://www.nasdaq.com/articles/why-lannett-lci-could-be-positioned-for-a-slump-2018-09-28", "https://www.nasdaq.com/articles/rigel-pharmaceuticals-rigl-in-focus%3A-stock-moves-6.2-higher-2018-09-18", "https://www.nasdaq.com/articles/ironwood-stock-up-heart-candidate-gets-fast-track-status-2018-09-14", "https://www.nasdaq.com/articles/kempharm-posts-positive-top-line-results-on-kp415-prodrug-2018-09-12", "https://www.nasdaq.com/articles/tilray-tlry-looks-good%3A-stock-adds-8.5-in-session-2018-09-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-aerovironment-biospecifics-codexis-avid-and-american", "https://www.nasdaq.com/articles/5-top-ranked-nasdaq-stocks-defying-worst-september-start-2018-09-10", "https://www.nasdaq.com/articles/tesaro-tsro-surges%3A-stock-moves-5.5-higher-2018-09-06", "https://www.nasdaq.com/articles/united-therapeutics-in-licenses-rights-to-ipf-candidate-2018-09-18", "https://www.nasdaq.com/articles/biogen-begins-phase-iii-study-on-ischemic-stroke-candidate-2018-09-05", "https://www.nasdaq.com/articles/4-stocks-with-recent-price-strength-to-maximize-your-gains-2018-09-04", "https://www.nasdaq.com/articles/affimed-afmd-soars%3A-stock-adds-10.8-in-session-2018-08-30", "https://www.nasdaq.com/articles/esperion-espr-combination-regimen-lowers-bad-cholesterol-2018-08-28", "https://www.nasdaq.com/articles/portola-pharmaceuticals-ptla-jumps%3A-stock-rises-9.1-2018-08-27", "https://www.nasdaq.com/articles/jazzs-jazz-leukemia-drug-vyxeos-gets-approval-in-europe-2018-08-27", "https://www.nasdaq.com/articles/ironwoods-linzess-gets-approval-in-japan-for-new-indication-2018-08-22", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-verso-johnson-outdoors-biospecifics-technologies-and-luxfer-holdings", "https://www.nasdaq.com/articles/biogen-begins-phase-iii-study-on-ischemic-stroke-candidate-2018-09-05", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-pcm-staar-surgical-verso-johnson-outdoors-and-biospecifics", "https://www.nasdaq.com/articles/5-stocks-with-recent-price-strength-to-enhance-your-returns-2018-08-17", "https://www.nasdaq.com/articles/biospecifics-technologies-bstc-q2-earnings-top-estimates-2018-08-09", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-biospecifics-technologies-bstc-2018-07-06", "https://www.nasdaq.com/articles/valeant-pharmaceuticals-vrx-catches-eye%3A-stock-jumps-8.9-2018-05-09", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-adamis-pharmaceuticals-admp-2018-04-10", "https://www.nasdaq.com/articles/vivus-vvus-qsymia-falters-in-a-highly-competitive-market-2018-08-22", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-karyopharm-therapeutics-kpti-2018-04", "https://www.nasdaq.com/articles/why-flexion-therapeutics-flxn-could-be-positioned-for-a-slump-2018-04-06", "https://www.nasdaq.com/articles/aratana-therapeutics-petx-soars%3A-stock-adds-12.4-in-session-2018-03-28", "https://www.nasdaq.com/articles/madrigal-pharmaceuticals-mdgl-soars%3A-stock-adds-6.5-in-session-2018-03-20", "https://www.nasdaq.com/articles/nektar-nktr-surges%3A-stock-moves-11-higher-2018-02-15", "https://www.nasdaq.com/articles/immunogen-imgn-soars%3A-stock-adds-10.3-in-session-2018-02-01", "https://www.nasdaq.com/articles/redhill-biopharma-rdhl-in-focus%3A-stock-moves-10.2-higher-2018-01-30", "https://www.nasdaq.com/articles/pacira-pharmaceuticals-pcrx-soars%3A-stock-adds-12.9-in-session-2018-04-09", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-december-1st-2017-12-01", "https://www.nasdaq.com/articles/new-strong-sell-stocks-november-27th-2017-11-27", "https://www.nasdaq.com/articles/new-strong-sell-stocks-november-22nd-2017-11-22", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-november-17th-2017-11-17", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-september-5th-2017-09-05", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-september-1st-2017-09-01", "https://www.nasdaq.com/articles/validea-motley-fool-strategy-daily-upgrade-report-8252017-2017-08-25", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-december-6th-2017-12-06", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-15th-2017-08-15", "https://www.nasdaq.com/articles/validea-motley-fool-strategy-daily-upgrade-report-8102017-2017-08-10", "https://www.nasdaq.com/articles/will-biospecifics-technologies-bstc-continue-to-surge-higher-2016-11-18", "https://www.nasdaq.com/articles/parexel-international-prxl-set-to-acquire-execupharm-2016-09-27", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-lennar-tops-q3-expectations-2016-09-20", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-biospecifics-technologies-bstc-2016-09-20", "https://www.nasdaq.com/articles/foamix-pharmaceuticals-fomx-jumps%3A-stock-rises-15.7-2016-09-13", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-21st-2017-08-21", "https://www.nasdaq.com/articles/sage-therapeutics%3A-breakthrough-status-for-depression-drug-2016-09-07", "https://www.nasdaq.com/articles/astrazeneca-asthma-drug-symbicort-positive-in-safety-trial-2016-09-01", "https://www.nasdaq.com/articles/dipexium-pharmaceuticals-dprx-in-focus%3A-stock-gains-8.5-2016-09-01", "https://www.nasdaq.com/articles/what-makes-collegium-pharmaceutical-coll-a-strong-sell-2016-08-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-mylan-teva-pharmaceutical-lannett-company-biospecifics", "https://www.nasdaq.com/articles/weakness-seen-in-jazz-pharmaceuticals-jazz-estimates%3A-should-you-stay-away-2016-08-29", "https://www.nasdaq.com/articles/forget-mylan-buy-these-3-drug-stocks-instead-2016-08-26", "https://www.nasdaq.com/articles/karyopharm-reports-positive-multiple-myeloma-study-data-2016-09-07", "https://www.nasdaq.com/articles/catalyst-pharmaceuticals-cprx-looks-good%3A-stock-up-6.3-2016-08-18", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-may-13th-2016-05-13", "https://www.nasdaq.com/articles/repros-rprx-q1-loss-narrower-yy-pipeline-focus-2016-05-11", "https://www.nasdaq.com/articles/jazz-jazz-tops-q1-earnings-raises-earnings-outlook-2016-05-11", "https://www.nasdaq.com/articles/biodelivery-bdsi-posts-line-loss-q1-revenues-miss-2016-05-11", "https://www.nasdaq.com/articles/ariad-aria-q1-loss-narrower-revenues-disappoint-revised-2016-05-11", "https://www.nasdaq.com/articles/why-biospecifics-technologies-bstc-stock-might-be-a-great-pick-2016-04-12", "https://www.nasdaq.com/articles/new-strong-buy-stocks-august-22nd-2016-08-22", "https://www.nasdaq.com/articles/mid-day-market-update-joy-global-drops-earnings-miss-methode-electronics-shares-spike", "https://www.nasdaq.com/articles/mid-day-market-update-national-penn-bancshares-surges-acquisition-news-vera-bradley-shares", "https://www.nasdaq.com/articles/biospecifics-announces-label-expansion-for-xiaflex-in-eu-analyst-blog-2015-02-05", "https://www.nasdaq.com/articles/auxilium-pharma-cuts-guidance-analyst-blog-2014-04-30", "https://www.nasdaq.com/articles/auxilium-pharma-beats-on-q4-earnings-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-monday-tale-of-the-tape-2014-03-03", "https://www.nasdaq.com/articles/pre-market-earnings-report-march-14-2016-ipar-pgem-ino-ta-rdnt-kpti-bstc-nerv-ears-strl", "https://www.nasdaq.com/articles/durata-therapeutics-drtx-jumps%3A-stock-rises-6.5-tale-of-the-tape-2014-02-19", "https://www.nasdaq.com/articles/positive-data-on-biospecifics-auxiliums-xiaflex-analyst-blog-2014-01-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-christmas-gift-uthr-tsro-tumbles-analyst-blog-2014-01-02", "https://www.nasdaq.com/articles/update-on-biospecifics-auxiliums-xiaflex-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/pipeline-progress-at-auxilium-pharma-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/auxilium-up-on-peyronies-approval-analyst-blog-2013-12-09", "https://www.nasdaq.com/articles/biospecifics-technologies-corp.-bstc-in-focus%3A-stock-moves-6.5-higher-tale-of-the-tape", "https://www.nasdaq.com/articles/alcobra-adhd-jumps%3A-stock-rises-8.5-tale-of-the-tape-2014-02-26", "https://www.nasdaq.com/articles/cadence-pharmaceuticals-inc.-cadx-jumps%3A-stock-rises-6.2-tale-of-the-tape-2013-12-04", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-tuesday-tale-of-the-tape-2013-12-03", "https://www.nasdaq.com/articles/data-on-auxilium-pharmas-xiaflex-analyst-blog-2013-11-22", "https://www.nasdaq.com/articles/regulatory-setback-for-forest-gedeon-analyst-blog-2013-11-22", "https://www.nasdaq.com/articles/qlt-qlti-surges%3A-stock-moves-11.8-higher-tale-of-the-tape-2013-11-21", "https://www.nasdaq.com/articles/biospecifics-technologies-bstc-looks-good%3A-stock-moves-9.5-higher-tale-of-the-tape-2013-11", "https://www.nasdaq.com/articles/will-biospecifics-technologies-corp.-bstc-continue-to-surge-higher-tale-of-the-tape-2013", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-monday-tale-of-the-tape-2013-12-09", "https://www.nasdaq.com/articles/strength-seen-in-cadence-pharmaceuticals-cadx%3A-stock-soars-34-tale-of-the-tape-2013-11-18", "https://www.nasdaq.com/articles/data-on-auxilium-pharmas-xiaflex-analyst-blog-2013-10-11", "https://www.nasdaq.com/articles/strength-seen-in-pharmacyclics-pcyc%3A-stock-rises-10.1-analyst-blog-2013-09-27", "https://www.nasdaq.com/articles/auxls-xiaflex-decision-delayed-analyst-blog-2013-08-29", "https://www.nasdaq.com/articles/jj-acquires-aragon-analyst-blog-2013-08-20", "https://www.nasdaq.com/articles/can-the-recent-uptrend-continue-for-biospecifics-technologies-corp.-bstc-tale-of-the-tape", "https://www.nasdaq.com/articles/company-news-for-may-13-2013-corporate-summary-2013-05-13", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-monday-tale-of-the-tape-2013-11-18", "https://www.nasdaq.com/articles/standard-review-for-auxiliums-drug-analyst-blog-2012-12-28", "https://www.nasdaq.com/articles/weak-quarter-from-auxilium-pharma-analyst-blog-2012-11-08", "https://www.nasdaq.com/articles/a-profitable-quarter-for-auxilium-analyst-blog-2012-08-02", "https://www.nasdaq.com/articles/loss-narrows-at-auxilium-analyst-blog-2012-05-14", "https://www.nasdaq.com/articles/merck-reports-strong-q3-results-gardasil-and-diabetes-med-2011-11-06", "https://www.nasdaq.com/articles/biotech-bargains-biotech-analysts-see-buying-opportunities-selloff-2011-08-16", "https://www.nasdaq.com/articles/positive-data-on-bstcs-xiaflex-analyst-blog-2013-04-01"], "Content": []}